
Organogenesis Holdings ORGO
€ 2.47
0.01%
Quartalsbericht 2025-Q3
hinzugefügt 06.11.2025
Organogenesis Holdings Kurzfristige Verbindlichkeiten 2011-2026 | ORGO
Kurzfristige Verbindlichkeiten Jährlich Organogenesis Holdings
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.5 M | 80.5 M | 75 M | 82.7 M | 68.2 M | 59.9 M | 66.4 M | 3.93 M | 478 K | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 82.7 M | 478 K | 57.2 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Arzneimittelhersteller
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | ||
|
AcelRx Pharmaceuticals
ACRX
|
2.65 M | - | 7.5 % | $ 6.35 M | ||
|
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | ||
|
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | ||
|
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M | ||
|
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | ||
|
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.1 | 2.84 % | $ 118 M | ||
|
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | ||
|
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | ||
|
Evolus
EOLS
|
75.3 M | $ 5.68 | 37.53 % | $ 366 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B | ||
|
Jupiter Wellness
JUPW
|
9.4 M | - | - | $ 33.6 M | ||
|
China Pharma Holdings
CPHI
|
5.02 M | $ 0.59 | 6.08 % | $ 10.3 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.81 | -16.81 % | $ 53.6 M | ||
|
Harrow Health
HROW
|
96.3 M | $ 40.02 | 3.65 % | $ 1.47 B | ||
|
Neoleukin Therapeutics
NLTX
|
23 M | - | - | $ 193 M | ||
|
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | ||
|
Emergent BioSolutions
EBS
|
651 M | $ 8.95 | 0.39 % | $ 458 M | ||
|
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | ||
|
Assertio Holdings
ASRT
|
93.4 M | $ 12.19 | 2.48 % | $ 866 M | ||
|
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
4.3 B | $ 5.67 | -0.87 % | $ 2.07 B | ||
|
Lannett Company
LCI
|
105 M | - | 1.15 % | $ 7.11 M | ||
|
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | ||
|
Rockwell Medical
RMTI
|
16.6 M | $ 0.91 | 1.03 % | $ 21.2 M | ||
|
Perrigo Company plc
PRGO
|
1.01 B | $ 11.71 | 2.81 % | $ 1.62 B | ||
|
TherapeuticsMD
TXMD
|
6.85 M | $ 2.25 | 1.35 % | $ 23.5 M | ||
|
Veru
VERU
|
11.9 M | $ 2.53 | 0.4 % | $ 341 M | ||
|
Viatris
VTRS
|
6.75 B | $ 14.74 | -1.04 % | $ 17.7 B | ||
|
Pacira BioSciences
PCRX
|
310 M | $ 22.92 | 3.69 % | $ 1.06 B | ||
|
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | ||
|
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | ||
|
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | ||
|
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | ||
|
Relmada Therapeutics
RLMD
|
12.2 M | $ 4.79 | 2.57 % | $ 144 M | ||
|
cbdMD
YCBD
|
8.62 M | $ 0.75 | -2.76 % | $ 3.23 M | ||
|
SCYNEXIS
SCYX
|
16.3 M | $ 0.76 | 1.22 % | $ 36.4 M | ||
|
Solid Biosciences
SLDB
|
30.3 M | $ 6.14 | 3.02 % | $ 251 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.74 | -0.36 % | $ 3.4 M | ||
|
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | ||
|
Tilray
TLRY
|
433 M | $ 7.33 | -0.48 % | $ 4.53 B | ||
|
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M |